Milestone Scientific, Inc. develops computer-controlled anesthetic delivery devices for the medical and dental markets in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent System that are used to control the flow rate of the anesthesia during the injection, which allows virtually painless injections for various dental procedures, including routine fillings, implants, root canals, and crowns. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, it provides CompuFlo Epidural, a computer controlled anesthesia system for use in various medical applications; CompuFlo Intra-Articular, a computer controlled injection system for administering corticosteroids and other medicaments; and Cosmetic Botulinum Injection device for the pain free injection of botulinum toxin. Further, the company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific, Inc. was incorporated in 1989 and is headquartered in Livingston, New Jersey.
IPO Year: 2015
Exchange: AMEX
Website: milestonescientific.com
Fastest customizable press release news feed in the world
ROSELAND, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2025. Neal Goldman, Chairman of the Board, stated, "We are pleased with our revenue performance in the second quarter, delivering a 25% increase in revenue to $2.3 million, driven by strong international dental sales, which more than doubled year-over-year. We also maintained a strong gross margin of 70%, reflecting the benefits of our high-margin dental business and disciplined cost management.
ROSELAND, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, August 15th, 2025, to discuss the company's financial results for the second quarter ended June 30, 2025, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 470429. A webcast and replay of the call may be accessed
ROSELAND. N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Jason Papes as Senior Vice President, Global Head of Sales and Marketing, effective immediately. Mr. Papes brings more than three decades of experience in sales, marketing, and business development within the healthcare industry, including leadership roles at large-cap medical technology companies and successful entrepreneurial ventures. His expertise spans orthopedics, neurology, pain management, and digital imaging, with a track record of building high-perfor
ROSELAND, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Eric C. Hines as Chief Executive Officer, effective immediately. Mr. Hines brings more than 25 years of leadership experience in scaling sales-driven enterprise software companies, serving customers across a range of industries, including healthcare. Most recently, he served as President of North America at Ex Libris, a division of Clarivate, where he led operations across the U.S., Canada, and Latin America and increased annual revenue from approximately $50 m
ROSELAND, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the initiation of commercial sales of its CompuFlo® Epidural System and related disposables at The Painless Center, located in Tenafly, New Jersey. The Painless Center is led by Chi-Shin Jason Chiu, MD, a double board-certified physician in Pain Management and Anesthesiology. A respected figure in interventional pain medicine, Dr. Chiu is known for his compassionate care and commitment to adopting state-of-the-art technologies to improve patient outcomes. He also serves as Direct
ROSELAND, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Shanth Thiyagalingam, BMedSc, MMKTG, MBA, has joined its Board of Directors, effective May 14, 2025. Mr. Thiyagalingam brings more than 20 years of global leadership in commercial scaling, product innovation, and strategic execution across the medical device and pharmaceutical industries. Newly appointed board member Shanth Thiyagalingam This appointment further supports Milestone Scientific's strategy to drive adoption of its CompuFlo® Epidural System, broaden access unde
ROSELAND, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and reported financial results for the first quarter ended March 31, 2025. Neal Goldman, Chairman and Interim Chief Executive Officer of Milestone Scientific, commented, "We are encouraged by the growing momentum in our medical segment, where first quarter results reflect increased traction for the CompuFlo® Epidural System. During the quarter, we were pleased to see new practices integrating CompuFlo into their workflows. These adoptions reflect both the clinical
Reports expansion of CompuFlo® Epidural System across additional pain management clinics and ambulatory surgery centers following Medicare price assignment in multiple U.S. states ROSELAND, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ended December 31, 2024. Neal Goldman, Chairman and Interim Chief Executive Officer of Milestone Scientific, stated, "While 2024 was a year of transition for Milestone Scientific, we laid the foundation for a strong rebound in 2025. We foc
ROSELAND, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that InfiniSurg, LLC, a premier ambulatory surgery center based in New Jersey, has incorporated the CompuFlo® Epidural System into its clinical practice. The device will be utilized by Roman Kosiborod, DO, a highly experienced anesthesiologist and pain management physician. This order was received through Milestone's distributor, Axial Biologics. Dr. Kosiborod brings over two decades of expertise in interventional pain management and ambulatory anesthesia. He is the Managing Dir
ROSELAND, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the commercial implementation of its CompuFlo® Epidural System at Pain Doctors Medical LLC, a specialized interventional pain management center. This rollout follows a successful evaluation led by Dr. Ilana Etelzon, MD, a board-certified expert in Interventional Pain Management and Physical Medicine & Rehabilitation Medicine, who has integrated the technology into her practice to enhance patient safety and procedural efficiency. The CompuFlo® Epidural System uses Milestone Scie
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)
4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)
4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)
4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)
4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)
4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)
4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)
4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)
4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)
4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)
8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
10-Q - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
10-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
NT 10-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
10-Q - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
Live Leadership Updates
ROSELAND. N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Jason Papes as Senior Vice President, Global Head of Sales and Marketing, effective immediately. Mr. Papes brings more than three decades of experience in sales, marketing, and business development within the healthcare industry, including leadership roles at large-cap medical technology companies and successful entrepreneurial ventures. His expertise spans orthopedics, neurology, pain management, and digital imaging, with a track record of building high-perfor
ROSELAND, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Eric C. Hines as Chief Executive Officer, effective immediately. Mr. Hines brings more than 25 years of leadership experience in scaling sales-driven enterprise software companies, serving customers across a range of industries, including healthcare. Most recently, he served as President of North America at Ex Libris, a division of Clarivate, where he led operations across the U.S., Canada, and Latin America and increased annual revenue from approximately $50 m
ROSELAND, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Shanth Thiyagalingam, BMedSc, MMKTG, MBA, has joined its Board of Directors, effective May 14, 2025. Mr. Thiyagalingam brings more than 20 years of global leadership in commercial scaling, product innovation, and strategic execution across the medical device and pharmaceutical industries. Newly appointed board member Shanth Thiyagalingam This appointment further supports Milestone Scientific's strategy to drive adoption of its CompuFlo® Epidural System, broaden access unde
ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that its Chief Executive Officer Arjan Haverhals will retire from his role as an officer of the company on December 31, 2024. Upon his retirement, Mr. Haverhals will continue to serve as a director on the Board and will provide consulting services to ensure continuity and support through the leadership transition. Mr. Haverhals' retirement, following a distinguished career of over 30 years in the medical device and pharmaceutical industries, reflects his desire to spend more ti
ROSELAND, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Dr. Didier Demesmin, MD, MBA, to the Board of Directors. Dr. Demesmin is an interventional pain medicine physician who is double board-certified in both anesthesiology and pain medicine. He is the founder of University Pain and Spine center, a well-respected interventional pain management and spine surgery clinic that operates 7 offices across New Jersey and New York. He is also the founder of STEMMEE Surgery Center, an ambulatory surgery center providing st
ROSELAND, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provides painless and precise injections, today announced it has entered into a distribution agreement with Sweden & Martina, a leading European dental distributor and manufacturer. Under the agreement, Sweden & Martina has been awarded the exclusive rights to market Milestone's STA Single Tooth Anesthesia System® (STA) in the new markets of Spain, Portugal and France. In addition, Sweden & Martina will replace the Company's current distributor in Italy and become its exclusive STA distributor in this market. Founded in 1972, Sweden &
ROSELAND, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Neal Goldman as Chairman of the Board of Directors. Mr. Goldman has served on the Company's board since 2019 and succeeds Leslie Bernhard, who has resigned following years of dedicated service. Mr. Goldman is the President and Founder of Goldman Capital Management, Inc., a family office since 2018, which was previously an investment advisory firm founded in 1985. He was First Vice President of Research at Shearson Lehman Hutton. He has also held senior po
ROSELAND, N.J., May 23, 2022 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Ms. Benedetta Casamento to the Company's Board of Directors. Ms. Casamento currently serves as a retail consultant specializing in finance, business operations, financial planning and analysis. Ms. Casamento previously served as Chairman and President of Allyke, Inc., an artificial intelligence company creating digital imagery insights for retail and other industries. She also served as CEO of Calypso St. Barth, a luxury lifestyle brand, as well as a consultan
ROSELAND, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has expanded its medical sales team including the appointment of Chet Trechock as VP of Sales Medical. Arjan Haverhals, CEO of Milestone Scientific, stated, "We are witnessing growing interest in our CompuFlo® Epidural Instrument and CathCheck™ System among anesthesiologists and hospitals. This interest is due, in part, to more hospitals re-opening their facilities to outside sales representatives, as well as the safety and economic value proposition of our system. Pr
Live finance-specific insights
ROSELAND, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2025. Neal Goldman, Chairman of the Board, stated, "We are pleased with our revenue performance in the second quarter, delivering a 25% increase in revenue to $2.3 million, driven by strong international dental sales, which more than doubled year-over-year. We also maintained a strong gross margin of 70%, reflecting the benefits of our high-margin dental business and disciplined cost management.
ROSELAND, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, August 15th, 2025, to discuss the company's financial results for the second quarter ended June 30, 2025, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 470429. A webcast and replay of the call may be accessed
Reports 57% increase in international dental sales for the third quarter of 2024 Advances commercial rollout of CompuFlo® Epidural System across additional pain management clinics following Medicare price assignment in multiple U.S. states ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today reported financial results for the third quarter ended September 30, 2024. Arjan Haverhals, CEO of Milestone Scientific, commented, "We are pleased to report a 22% year-over-year increase in total revenue, reaching $2.5 million for t
ROSELAND, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Friday, November 15th, 2024, to discuss the company's financial results for the third quarter ended September 30, 2024, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 169295. A webcast and replay of the call may be acc
Secured Medicare price assignment for the CompuFlo® Epidural System in multiple U.S. states Gross margin for the second quarter of 2024 increased to 76.1% from 65.0% for the same period last year driven by an increase in U.S. e-commerce sales ROSELAND, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2024. Arjan Haverhals, CEO and President of Milestone Scientific, commented, "We are successfully advancing our reimbursement strategy for the CompuFlo®
ROSELAND, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Thursday, August 15th, 2024, to discuss the company's financial results for the second quarter ended June 30, 2024, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 959238. A webcast and replay of the call may be accesse
Sales through new online portal increase 31% over the same period last year Gross margin for the first quarter of 2024 increases to 74.5% from 72.7% for the same period last year Reports steady progress on reimbursement strategy for the CompuFlo® Epidural System ROSELAND, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and announces financial results for the first quarter ended March 31, 2024. Arjan Haverhals, CEO and President of Milestone Scientific, stated, "I am pleased to report our domestic, direct sales strate
ROSELAND, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Thursday, May 16th, 2024, to discuss the company's financial results for the first quarter ended March 31, 2024, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 525731. A webcast and replay of the call may be accessed at
ROSELAND, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and announces financial results for the year ending December 31, 2023. Arjan Haverhals, CEO and President of Milestone Scientific, stated, "We achieved solid financial results in 2023, with revenue increasing 11.6% and gross profit increasing 39%. We attribute this performance to the success of our new online sales portal for the STA Single Tooth Anesthesia System® (STA) in the U.S., which has enhanced our margins, while providing us a closer relationship wi
ROSELAND, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Monday, April 1, 2024, to discuss the company's financial results for 2023, as well as the company's corporate progress and other developments The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 222156. A webcast and replay of the call may be accessed at Webcast URL: https://www.webcaster4